HR Execs on the Move

Delphinus Medical Technologies

www.delphinusmt.com

 
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Delphinus is committed to creating improved imaging methods that assist medical professionals to better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, without the concern of radiation or pain. Headquartered in Plymouth, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Known as ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Med-Response Inc

Med-Response Inc is a Bluefield, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridian Health

Meridian Health is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Wall Township, NJ. To find more information about Meridian Health, please visit www.meridianhealth.com

TherOx

TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.

Sentage Corporation

Sentage Corporation is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Incapital

Incapital was founded in 1999 with the mission of providing securities firms and individual investors more efficient access to corporate bonds. While Incapital`s expertise in underwriting and distributing investment-grade corporate bonds remains a core competency, the firm now originates and distributes offerings across multiple asset classes. In addition to its broker-dealer and bank partners, Incapital now serves institutional investors and wealth managers. With over 150 employees in multiple offices in North America, the firm represents over 400 issuing entities and serves 800+ distribution partners. Incapital continues to provide market leadership with a growing range of product offerings, strong strategic partnerships and innovative technology.